Primary PFS and safety analyses of a randomized phase III study of carboplatin plus paclitaxel plus /- bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150) Meeting Abstract

International Collaboration

cited authors

  • Reck, M.; Socinski, M. A.; Cappuzzo, F.; Orlandi, F.; Stroyakovskiy, D.; Nogami, N.; Rodriguez-Abreu, D.; Moro-Sibilot, D.; Thomas, C. A.; Barlesi, F.

authors

Publication Date

  • April 1, 2018

webpage

published in

category

start page

  • S77

end page

  • S78

volume

  • 13

issue

  • 4